ITEM 7.01 REGULATION FD DISCLOSURE
On August 20, 2014, we issued a press release announcing that we had closed our
underwritten public offering of 3,333,333 shares of common stock at a per share
price of $3.75 and warrants to purchase up to the same number of shares of
common stock at a per warrant price of $0.01; plus the issuance of approximately
an additional 1,110,000 shares and warrants in consideration of the cancellation
of $4,000,000 principal amount of convertible debentures plus accrued interest.
The press released also announced that the underwriter partially exercised the
over-allotment option to purchase an additional 250,000 shares of common stock
and acquired warrants to purchase 500,000 shares of common stock. A copy of the
press release is furnished as Exhibit 99.1 and is incorporated by reference
Also on August 20, 2014, we issued a press release announcing recent company
highlights and our results for the second quarter and six months ended June 30,
2014.A copy of the press release is furnished as Exhibit 99.2 and is
incorporated by reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
99.1 Press release dated August 20, 2014, entitled "Cellectar
Biosciences Announces Closing of Public Offering and Partial
Exercise of Underwriter's Over-Allotment Option"
99.2 Press release dated August 20, 2014, entitled "Cellectar
Biosciences Reports Second Quarter 2014 Financial Results and